NIDA/SAMHSA Blending Initiative Overview: A Focus on Medication Assisted Treatment
|
|
|
- Maximillian Miles
- 8 years ago
- Views:
Transcription
1 NIDA/SAMHSA Blending Initiative Overview: A Focus on Medication Assisted Treatment Thomas E. Freese, Ph.D., & Beth Rutkowski, M.P.H. AHSR, October 2011
2 What s the Issue? A significant delay exists between the publication of research results and impact on treatment delivery* To reduce the gap, NIDA and SAMHSA/CSAT have partnered to disseminate research findings for application in the treatment community through the Blending Initiative * Lamb, S., Greenlick, M.R., & McCarty, D., Eds. (1998). Bridging the gap between practice and research: Forging partnerships with community based drug and alcohol treatment. Institute of Medicine, National Academy Press: Washington, DC.
3 NIDA/SAMHSA Blending Initiative According to Webster s Dictionary definition To Blend means: a. combine into an integrated whole; b. produce a harmonious effect webster.com/dictionary/blend
4 What is the Blending Initiative? GOAL: To move important scientific findings into mainstream addiction treatment Developed in 2001, NIDA and SAMHSA s Center for Substance Abuse Treatment came together to work on a common vision: Improve substance use disorder treatment and accelerate the dissemination of research based findings into community based practice.
5 Addiction Technology Transfer Center Network
6 The NIDA/SAMHSA Blending Initiative encompasses three components: Regional Blending Conferences State Agency Partnerships Blending Teams
7 Regional Blending Conferences Enhance bi directional communication among: researchers, practitioners, and policy makers Share innovative scientific findings about drug abuse and addiction Convene in different regions of the country
8 State Agency Partnerships NIDA and SAMHSA work closely with federal and state policy makers to help identify strategies to accelerate the adoption of science based practices.
9 Blending Teams Use NIDA research findings to design userfriendly science based tools for use in treatment settings soon after research results are published. Teams include members from: SAMHSA CSAT Addiction Technology Transfer Center (ATTC) Network, NIDA researchers, and Community treatment providers participating in the NIDA Drug Abuse Treatment Clinical Trials Network (CTN).
10 Blending Process Selected CTN protocols or other NIDA Research Hand-Off Meeting Create the charge for Blending Team Blending Team Develop dissemination strategies and products
11 Current Blending Initiative Packages
12 Blending Initiative Packages Available in Spanish
13 A Focus on Medication Assisted Treatment BUPRENORPHINE/NALOXONE
14 Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals Buprenorphine and Buprenorphine/Naloxone Help Patients Quit Opiate Abuse Goal: to disseminate information and enhance awareness among multidisciplinary addiction professionals about buprenorphine treatment
15 Buprenorphine Treatment: A Training for Multidisciplinary Products in Package: Addiction Professionals 6 hour classroom training including a training manual, PowerPoint slides, and the short movie, Put Your Smack Down! A Video About Buprenorphine Annotated bibliography and research articles
16 Short Term Opioid Withdrawal Using Buprenorphine Goal: to instruct treatment providers about the 13 day buprenorphine intervention. Product in Package: 4 hour classroom training program including PowerPoint slides and a CD Buprenorphine/Naloxone Buprenorphine
17 Results: Present and Opioid Negative 0001 (Inpatient) % of Individuals present at end of taper Clonidine Bup/Nx Day 3-4 Day 7-8 Day Day % of opioid free urines
18 % of Individuals present at end of taper Results: Present and Opioid Negative 0002 (Outpatient) Clonidine Bup/Nx Day 3-4 Day 7-8 Day Day % of opioid free urines
19 Buprenorphine Treatment for Young Adults: Findings and Strategies from a NIDA Clinical Trials Network Study Goal: to present the results of a buprenorphine trial conducted with young adults. Product in Package: 3 hour classroom training program including PowerPoint slides and a CD
20 Results: Opioid Positive Urine Tests
21 Buprenorphine Related Blending Initiative Products OUTCOMES
22 The ATTC Network has: Completed 764 Blending Product Trainings from January 2005 September 2011 (with a total of 15,958 people) 134 Buprenorphine Treatment (3,317 people) 18 Short Term Opioid Withdrawal Using Buprenorphine (801 people) 22 Buprenorphine for Young Adults (318 people)
23 The ATTC Network has: Printed and distributed 567,000 brochures introducing each of the Blending Initiatives materials to the field Recruited and prepared trainers in every ATTC Region to teach the Blending Initiative materials Developed and distributed ancillary products to enhance the reach of the official NIDA products, such as curriculum infusion packages for addiction studies educators at colleges and universities.
24 The ATTC Network has: Presented information on the Blending Initiative at State, Regional, and National conferences to: Increase awareness about the training materials Identify new opportunities to train using the blending products
25 Products Currently Under Development 1. MI:PRESTO (Motivational Incentives: Positive Reinforcers to Enhance Successful Treatment Outcomes) 2. POATS (Prescription Opioid Addiction Treatment Study)** 3. Onsite HIV Rapid Testing Blending Initiative
26 Product Dissemination Download the Products for FREE! Find upcoming trainings offered through SAMHSA s ATTC Network! Go to
27 For more information Thomas E. Freese, Ph.D Beth A. Rutkowski, M.P.H
Short Term Opioid Withdrawal Using Buprenorphine
Short Term Opioid Withdrawal Using Buprenorphine ٢ Table of Contents Introduction to the Training... 5 Background Information: NIDA-SAMHSA Blending Initiative... 5 Focus on Buprenorphine... 5 Blending
BUPRENORPHINE TREATMENT
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
Addiction Technology Transfer Center
Addiction Technology Transfer Center Unifying science, education and services to transform lives. www.nattc.org 1 The Addiction Technology Transfer Center Network Funded by Substance Abuse and Mental Health
BUPRENORPHINE TREATMENT
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
BRIDGING THE GAP. between een Research and Practice. The First Decade. National Drug Abuse Treatment Clinical Trials Network
BRIDGING THE GAP between een Research and Practice National Drug Abuse Treatment Clinical Trials Network The First Decade CTN Across the Nation Regional Research and Training Center (RRTC) States with
9/18/2013. Buprenorphine for Opioid Dependence: NIDA/SAMHSA Blending Initiative. According to the Webster Dictionary definition
2013 Annual Conference for Behavioral Health Wichita, Kansas September 18, 2013 Alex Barajas-Muñoz, MS Buprenorphine for Opioid Dependence: A Training for Multidisciplinary Addiction Professionals NIDA/SAMHSA
Prescription Opioid Addiction Treatment Study (POATS)
Prescription Opioid Addiction Treatment Study (POATS) Findings and Strategies from a NIDA Clinical Trials Network Study Training Manual Prescription Opioid Addiction Treatment Study Findings and Strategies
Web-Based Resources. Locating Treatment
Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate
This module will assist participants to:
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module V: Coordinated Care Effective Coordination of Care Effective coordination combines the strengths of various systems
Various therapies are used in the
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all
Best Practices in Addiction Treatment:
Best Practices in Addiction Treatment: A Workshop Facilitator s Guide Addiction Technology Transfer Center Network ATTC National Office Kansas City, Missouri Unifying science, education and services to
BUPRENORPHINE TREATMENT. Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist s Courses
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist s Courses A Generalist s course Developed by the Mountain West ATTC - 1 - Introduction The main goal
Free Additional Resources
Free Additional Resources Substance Abuse and Mental Health Services Administration Treatment Improvement Protocols The Substance Abuse and Mental Health Services Administration (SAMHSA) offers free Treatment
How To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
BUPRENORPHINE TREATMENT. Curriculum Infusion Package (CIP)For Infusion into Graduate Level Courses
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP)For Infusion into Graduate Level Courses Using Buprenorphine in the Treatment of Opioid Addiction Developed by the Mountain West ATTC - 1 - Introduction
Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD
Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS NIDA/SAMHSA Blending Initiative According to the Webster Dictionary definition To Blend means: a. combine into an integrated
Use of Pharmacotherapies by Substance Abuse Treatment Facilities
Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1
State Perspectives on Buprenorphine and Office-Based Treatment
State Perspectives on Buprenorphine and Office-Based Treatment The National Association of State Alcohol and Drug Abuse Directors (NASADAD) For the Center for Substance Abuse Treatment (CSAT) With support
Treatment of Prescription Opioid Dependence
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
An Overview of Evidence-Based Practices: Implementing Science-Based Interventions in Practical Settings
An Overview of Evidence-Based Practices: Implementing Science-Based Interventions in Practical Settings An Overview of Evidence-Based Practices: Implementing Science-Based Interventions in Practical Settings
State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff
State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff Funding Source: Grant No. 053773 Robert Wood Johnson Foundation Substance Abuse Policy Research
Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Opioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Implementation in Community
Medication-Assisted i t d Treatment t Implementation in Community Correctional Environments (MATICCE) CJ-DATS is funded by NIDA in collaboration with SAMHSA and BJA. What is Medication-Assisted Treatment
SBIRT INITIATIVE. SBIRT Process. SBIRT Overview. The New Hampshire Youth Screening, Brief Intervention and Referral to Treatment (SBIRT)
Overview INITIATIVE New Hampshire Youth Screening, and Referral to Treatment Initiative The New Hampshire Youth Screening, and Referral to Treatment () Initiative of the New Hampshire Charitable Foundation
Financial Disclosures
Opioid Agonist Therapy: To Maintain or Not To Maintain - A Case Discussion PCSS-MAT American Psychiatric Association Drs. Ed Salsitz, John Renner, Timothy Fong April 14, 2015 Financial Disclosures Edwin
SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK
National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal
Using Buprenorphine in an Opioid Treatment Program
Using Buprenorphine in an Opioid Treatment Program Thomas E. Freese, PhD Director of Training, UCLA Integrated Substance Abuse Programs Director, Pacific Southwest Addiction Technology Transfer Center
Addiction Messenger Part 1: Medication-Assisted Treatment - Setting the Context
Addiction Messenger Part 1: - Setting the Context "When you love someone who suffers from the disease of addiction you await the phone call. There will be a phone call. T he sincere hope is that the call
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
NIDA NATIONAL INSTITUTE ON DRUG ABUSE
Betty Tai, Ph.D. Director Center for the Clinical Trials Network National Institute on Drug Abuse NIDA NATIONAL INSTITUTE ON DRUG ABUSE Institute of Medicine, 1998 Research Bridging the Gap Practice The
PERFORMANCE MEASURES FOR SUBSTANCE USE DISORDERS: CURRENT KNOWLEDGE AND KEY QUESTIONS
PERFORMANCE MEASURES FOR SUBSTANCE USE DISORDERS: CURRENT KNOWLEDGE AND KEY QUESTIONS Deborah Garnick Constance Horgan Andrea Acevedo, The Heller School for Social Policy and Management, Brandeis University
The Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index
The Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index Heather J. Gotham, PhD, 1 Jessica L. Brown, PhD, 2 Joseph E. Comaty, PhD, MP, 2,3 Mark McGovern, PhD 4 & Ronald E. Claus, PhD 5 1
Opioid Addiction Treatment. Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine
Opioid Addiction Treatment Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine 1 Continuity of Care: A Critical Goal Is shorter cheaper? Re-hospitalization in 296 dependent patients
Module II. Opioids 101
Module II Opioids 101 Module II: Opioids 101 Module II is designed to introduce participants to basic facts about opioids, including information on pharmacology, acute and long-term effects, and basic
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
Motivational Interviewing Training Program FREE
Motivational Interviewing Training Program FREE PROGRAM OVERVIEW Mid-America ATTC, in partnership with the Missouri Department of Mental Health, Division of Behavioral Health is providing FREE training
Patients are still addicted Buprenorphine is simply a substitute for heroin or
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute
Behavioral Health is Essential to Health Prevention Works Treatment is Effective People Recover
Prescription Opioid Addiction Treatment Study Findings and Strategies from a NIDA Clinical Trials Network Study 2013 Midwest Conference on Problem Gambling and Substance Abuse Alex Barajas-Muñoz Behavioral
Update on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines
OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines Guideline Evaluation and Treatment Planning Discharge Planning Admission Criteria Continued Stay Criteria Discharge
One example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section TITLE I: PREVENTION SUBTITLE A- PRESCRIBER EDUCATION PRACTITIONER EDUCATION This subtitle requires practitioners who
Findings and Recommendations
6 Findings and Recommendations The committee s review of current research, models for collaboration between research and practice, community-based organizations, and dissemination strategies led to findings
Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA )
The Determinations Report: A Report On the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 ( DATA ) Submitted by the Center for Substance Abuse Treatment, Substance Abuse
Information for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
CT-167. February 2000
T E S T I M O N Y R What is SAMHSA Doing to Help Communities Make Good Decisions About the Allocation of Scarce Treatment Resources? Martin Y. Iguchi CT-167 February 2000 Testimony presented to the Subcommittee
Care Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
MEDICAL POLICY Treatment of Opioid Dependence
POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which
Training in SBIRT in Medical Schools in the United States:
Training in SBIRT in Medical Schools in the United States: An Examination of Physician Education and Training on Conducting Screenings, Brief Interventions, and Referrals to Treatment Manu Singh, Ph.D.,
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
Prior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
Findings and strategies from a NIDA Clinical Trials Network Study
Short-Term Opioid Withdrawal Using Buprenorphine Findings and strategies from a NIDA Clinical Trials Network Study NIDA/SAMHSA Blending Initiative According to the Webster Dictionary definition To Blend
Evidence Based Approaches to Addiction and Mental Illness Treatment for Adults
Evidence Based Practice Continuum Guidelines The Division of Behavioral Health strongly encourages behavioral health providers in Alaska to implement evidence based practices and effective program models.
Bridges have been built: Is anyone using them?
Bridges have been built: Is anyone using them? Richard A. Rawson, Ph.D, Professor Supported by: National Institute on Drug Abuse (NIDA) Pacific Southwest Technology Transfer Center (SAMHSA) United Nations
Practice Protocol. Buprenorphine Guidance Protocol
Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol
Prescriber Behavior, Pain Treatment and Addiction Treatment
Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Substance Abuse Treatment Services Objectives and Performance Measures Progress: First Annual Report
Report to The Vermont Legislature Substance Abuse Treatment Services Objectives and Performance Measures Progress: First Annual Report In Accordance with Act 179 (2014) Sec. E.306.2 (a)(1) Submitted to:
Jennifer Sharpe Potter, PhD, MPH Associate Professor Division of Alcohol and Drug Addiction Department of Psychiatry
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) Jennifer
Provider enews TREATING PRESCRIPTION DRUG ADDICTION
Provider enews TREATING PRESCRIPTION DRUG ADDICTION Treating addiction to prescription opioids July 2012 Several options are available for effectively treating prescription opioid addiction. These options
MIA:STEP MIA: Supervisory Tools for Enhancing Proficiency MOTIVATIONAL I NTERVIEWING I A SSESSMENT: A product of the NIDA-SAMHSA Blending Initiative
MIA: M MOTIVATIONAL I NTERVIEWING I A SSESSMENT: A A product of the NIDA-SAMHSA Blending Initiative Supervisory Tools for Enhancing Proficiency Motivational Interviewing Assessment: Supervisory Tools for
Federal Regulations For Prescribing Scheduled Controlled Substances
Federal Regulations For Prescribing Scheduled Controlled Substances HEIT TEMPLATE.PPT 1 Central Principle of Balance With the Use of Controlled Substances Dual imperative of government Establish a system
Medication Assisted Treatments for Opioid Dependence & Barriers to Implementation
Medication Assisted Treatments for Opioid Dependence & Barriers to Implementation 9th Annual Midwest Conference on Problem Gambling and Substance Abuse Erin L. Winstanley, Ph.D. University of Cincinnati
Opioid overdose can occur when a patient misunderstands the directions
Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
Ohio Legislative Service Commission
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer
Journal of Substance Abuse Treatment 26 (2004) 203 208 Regular article Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer Dennis McCarty a, *, Traci
SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK
National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal
Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015
Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid
Medical and Professional Education
Medical and Professional Education Presented by the Hazelden Betty Ford Foundation Summer Institute for Medical Students Professionals in Residence Medical Education Partnership Addiction Medicine Fellowship
Performance Standards
Performance Standards Co-Occurring Disorder Competency Performance Standards are intended to provide a foundation and serve as a tool to promote continuous quality improvement and progression toward best
May 21, 2015 Joint Committee on Finance Paper #352
Legislative Fiscal Bureau One East Main, Suite 301 Madison, WI 53703 (608) 266-3847 Fax: (608) 267-6873 Email: fiscal.bureau@legis.wisconsin.gov Website: http://legis.wisconsin.gov/lfb May 21, 2015 Joint
Substance Abuse Prevention
Prescription Drug Abuse Prevention & -Early Intervention (SBIRT) Barry R. Donovan, Ph.D. NYS OASAS Bureau of Prevention Services Research Application Unit Substance Abuse Prevention What do Heroin, Rx
Prescription Drug Abuse Prevention & -Early Intervention (SBIRT)
Prescription Drug Abuse Prevention & -Early Intervention (SBIRT) Barry R. Donovan, Ph.D. NYS OASAS Bureau of Prevention Services Research Application Unit Substance Abuse Prevention What do Heroin, Rx
Response by the California Association for Alcohol/Drug Educators
Response by the California Association for Alcohol/Drug Educators To Workforce Development Needs in the Field of Substance Use Disorders Supplement to Stakeholder Recommendations for Mental Health and
National Perspectives in Medication Assisted Treatment
National Perspectives in Medication Assisted Treatment Addiction Medicine Asheville March 21,2014 Melinda Campopiano, MD Medical Officer Substance Abuse & Mental Health Services Administration Guten Appetit
DrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
Medication-Assisted Treatment for Opioid Addiction
Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid
How To Find Out What Your Facility Offers
U.S. Department of Health and Human Services FORM APPROVED: OMB No. 0930-0106 APPROVAL EXPIRES: 01/31/2016 See OMB burden statement on last page National Survey of Substance Abuse Treatment Services (N-SSATS)
Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:
Section XX. Definitions. Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended (1) by striking clause (ii) and inserting the following: (ii) The term qualifying practitioner
Family Involvement in Adolescent Substance Abuse Treatment February, 2008
Family Involvement in Adolescent Substance Abuse Treatment February, 2008 Sharon L. Smith, Steve Hornberger, MSW, Sherese Brewington-Carr, M.H.S. Cathy Finck, Cassandra O Neill, MA, Doreen Cavanaugh, Ph.D.,
Program Assistance Letter
Program Assistance Letter DOCUMENT NUMBER: 2004-01 DATE: December 5, 2003 DOCUMENT TITLE: Use of Buprenorphine in Health Center Substance Abuse Treatment Programs TO: All Bureau of Primary Health Care
American Society of Addiction Medicine
American Society of Addiction Medicine Public Policy Statement on Office-based Opioid Agonist Treatment (OBOT) BACKGROUND Methadone maintenance treatment of opioid addiction was developed in 1965 and implemented
Medication-Assisted Addiction Treatment
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Summary: There are four major initiatives underway that address integration of substance abuse care with physical and mental health.
Summary: Section E.306.2(b)(1) requires the Secretary of Administration and the Chief of Health Care Reform to submit a report on current and additional strategies to achieve a more comprehensive health
Resources for the Prevention and Treatment of Substance Use Disorders
Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug
2011 State Profile California
20 State Profile California National Survey of Substance Abuse Treatment Services (N-SSATS) The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing
Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to
2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users
Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users Jennifer R. Havens, PhD, MPH Carrie B. Oser, PhD Carl G. Leukefeld, PhD Study Objective The objective
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES. PART He-W 513 SUBSTANCE USE DISORDER (SUD) TREATMENT AND RECOVERY SUPPORT SERVICES
CHAPTER He-W 500 MEDICAL ASSISTANCE PART He-W 513 SUBSTANCE USE DISORDER (SUD) TREATMENT AND RECOVERY SUPPORT SERVICES He-W 513.01 Purpose. The purpose of this part is to establish the procedures and requirements
Strengthening Professional Identity
Strengthening Professional Identity Challenges of the Addictions Treatment Workforce A Framework for Discussion Executive Summary December 2006 Acknowledgments Abt Associates Incorporated prepared this
INSTRUCTIONS AND PROTOCOLS FOR THE IMPLEMENTATION OF MEDICATION-ASSISTED TREATMENT FOR OPIOID/OPIATE DEPENDENCE
201 Mulholland Bay City, MI 48708 P 989-497-1344 F 989-497-1348 www.riverhaven-ca.org Title: MAT Protocol Original Date: March 30, 2009 Latest Revision Date: December 16, 2013 Approval/Release Date: January
What Will it Take to Implement Evidence-Based Practices Statewide
What Will it Take to Implement Evidence-Based Practices Prepared for Barbara Lucenko Division of Alcohol and Substance Abuse PO Box 45330 Olympia, WA 98504-5330 Prepared by Katherine E. Laws, B.A. Ryan
Federal Response to Opioid Abuse Epidemic
Healthcare Committee Federal Response to Opioid Abuse Epidemic On May 1, 20215 the Energy and Commerce Subcommittee on Oversight and Investigations held a hearing entitled What is the Federal Government
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to
2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose: